Back
ARS Pharmaceuticals Quote, Financials, Valuation and Earnings
Sponsored
SPRY
Sponsored
Free 23-page book shares my #1 indicator to use
Here's the 23-page free book.
Sell
35
SPRY
ARS Pharmaceuticals
Last Price:
14.87
Seasonality Move:
-2.91%
7 Day Trial
ALL ACCESS PASS
$
7
"The Next Apple?" - Mode's Growth Story is Turning Heads
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.ARS Pharmaceuticals Price Quote
$14.87
+0.82 (+5.84%)
(Updated: September 19, 2024 at 6:55 PM ET)
ARS Pharmaceuticals Key Stats
Sell
35
ARS Pharmaceuticals (SPRY)
is a Sell
Day range:
$13.10 - $14.32
52-week range:
$2.55 - $16.50
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
6.33%
Volume:
1.1M
Avg. volume:
1.5M
1-year change:
88.84%
Market cap:
$1.4B
Revenue:
$30K
EPS:
$-0.47
How Much Does ARS Pharmaceuticals Make?
Data Unavailable
Is ARS Pharmaceuticals Growing As A Company?
-
What Is ARS Pharmaceuticals's Growth Rate Quarterly?
Quarterly YoY revenue growth is 49% -
What Is ARS Pharmaceuticals's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
ARS Pharmaceuticals Stock Price Performance
-
Did ARS Pharmaceuticals Stock Go Up Last Month?
ARS Pharmaceuticals share price went up by 5.4% last month -
Did SPRY's Share Price Rise Over The Last Year?
SPRY share price rose by 88.84% over the past 1 year
What Is ARS Pharmaceuticals 52-Week High & Low?
-
What Is ARS Pharmaceuticals’s 52-Week High Share Price?
ARS Pharmaceuticals has traded as high as $16.50 over the past 52 weeks -
What Is ARS Pharmaceuticals’s 52-Week Low Share Price?
ARS Pharmaceuticals has traded as low as $2.55 over the past 52 weeks
ARS Pharmaceuticals Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy ARS Pharmaceuticals?
-
How Much Debt Does ARS Pharmaceuticals Have?
Total long term debt quarterly is $0 -
How Much Cash Does ARS Pharmaceuticals Have?
Cash and short term investments quarterly total is $218.7M -
What Is ARS Pharmaceuticals’s Book Value Per Share?
Book value per share is 2.22
Is ARS Pharmaceuticals Cash Flow Positive?
-
What Is SPRY Cash Flow From Operations?
Cash flow from operations (TTM) is -$44.2M -
What Is ARS Pharmaceuticals’s Cash Flow From Financing?
Cash flow from financing (TTM) is $3.5M -
What Is ARS Pharmaceuticals’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$41.8M
ARS Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
SPRY return on invested capital is -19.4% -
What Is ARS Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is -18.84% -
What Is SPRY Return On Equity?
ROE is a measure of profitability and is -19.4%
ARS Pharmaceuticals Earnings Date & Stock Price
-
What Is ARS Pharmaceuticals's Stock Price Today?
A single share of SPRY can be purchased today for 14.05 -
What Is ARS Pharmaceuticals’s Stock Symbol?
ARS Pharmaceuticals trades on the nasdaq under the ticker symbol: SPRY -
When Is ARS Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for ARS Pharmaceuticals is scheduled on November 8, 2024 -
When Is SPRY's next ex-dividend date?
ARS Pharmaceuticals's next ex-dividend date is September 20, 2024 -
How To Buy ARS Pharmaceuticals Stock?
You can buy ARS Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
ARS Pharmaceuticals Competitors
-
Who Are ARS Pharmaceuticals's Competitors?
Below is a list of companies who compete with ARS Pharmaceuticals or are related in some way:
ARS Pharmaceuticals Dividend Yield
-
What Is SPRY Dividend Yield?
ARS Pharmaceuticals’s dividend yield currently is 0% -
What Is ARS Pharmaceuticals’s Payout Ratio?
ARS Pharmaceuticals’s payout ratio is 0% -
When Did ARS Pharmaceuticals Last Pay A Dividend?
The latest dividend pay date is September 20, 2024 -
What Is ARS Pharmaceuticals’s Dividend Per Share?
ARS Pharmaceuticals pays a dividend of $0.00 per share
ARS Pharmaceuticals Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | -13.04% |
Revenue: | 4900% | -25% |
Analyst Recommendations
Buy Recommendations: | 4 |
---|---|
Hold Recommendations: | 0 |
Sell Recommendations: | 0 |
Price Target: | 24.33 |
Upside from Last Price: | 73.19% |